Zealand Pharma (LSE:0NZU) - Cotización, noticias y análisis

Resumen de acción 0NZU

Zealand Pharma A/S, empresa de biotecnología, se dedica al descubrimiento, desarrollo y comercialización de medicamentos a base de péptidos en Dinamarca.

Acerca de la empresa

0NZU fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 26.69%

Los analistas coinciden en que el precio de las acciones subirá un 30.6%

Análisis de riesgos

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Zealand Pharma A/S

Genus

LSE:GNS

UK£1.2b

PureTech Health

LSE:PRTC

UK£583.7m

NIOX Group

AIM:NIOX

UK£301.0m

Bioventix

AIM:BVXP

UK£225.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Zealand Pharma
Historical stock prices
Current Share Price	kr.627.00
52 Week High	kr.749.00
52 Week Low	kr.212.20
Beta	0.67
1 Month Change	-8.00%
3 Month Change	33.30%
1 Year Change	178.86%
3 Year Change	219.50%
5 Year Change	362.90%
Change since IPO	835.82%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	0NZU	GB Biotechs	Mercado GB
7D	0.2%	3.8%	1.2%
1Y	178.9%	-25.7%	2.3%

Rentabilidad vs. Industria: 0NZU superó al sector UK Biotechs , que obtuvo un rendimiento del -27.7% el año pasado.

Rentabilidad vs. Mercado: 0NZU superó al mercado UK, que obtuvo un rendimiento del 0.6% el año pasado.

Volatilidad de los precios

Is 0NZU's price volatile compared to industry and market?
0NZU volatility
0NZU Average Weekly Movement	10.2%
Biotechs Industry Average Movement	7.3%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.4%
10% least volatile stocks in GB Market	2.7%

Precio estable de las acciones: El precio de las acciones de 0NZU ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 0NZU(10%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de UK.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1997	253	Adam Steensberg	www.zealandpharma.com

Zealand Pharma A/S, empresa de biotecnología, se dedica al descubrimiento, desarrollo y comercialización de medicamentos a base de péptidos en Dinamarca. Cuenta con una cartera de medicamentos centrados en enfermedades gastrointestinales y metabólicas, así como en otras áreas de enfermedades especializadas con necesidades médicas no cubiertas. La empresa ofrece Dasiglucagon, una jeringa o autoinyector de un solo uso para el tratamiento de la hipoglucemia grave; y sistemas de páncreas artificial bihormonales Dasiglucagon que contienen insulina y dasiglucagon.

Resumen de fundamentos de Zealand Pharma A/S

¿Cómo se comparan los beneficios e ingresos de Zealand Pharma con su capitalización de mercado?
Estadísticas fundamentales de 0NZU
Capitalización bursátil	kr.39.23b
Beneficios(TTM)	-kr.703.74m
Ingresos (TTM)	kr.342.79m

114.5x

Ratio precio-ventas (PS)

-55.7x

Ratio precio-beneficio (PE)

¿Está 0NZU sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 0NZU
Ingresos	kr.342.79m
Coste de los ingresos	kr.688.10m
Beneficio bruto	-kr.345.31m
Otros gastos	kr.358.43m
Beneficios	-kr.703.74m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 16, 2024

Beneficios por acción (BPA)	-11.30
Margen bruto	-100.74%
Margen de beneficio neto	-205.30%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado 0NZU a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 0NZU

Recompensas

Análisis de riesgos

Competidores de Zealand Pharma A/S

LSE:GNS

UK£1.2b

LSE:PRTC

UK£583.7m

AIM:NIOX

UK£301.0m

AIM:BVXP

UK£225.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Recent updates

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings released: kr.4.19 loss per share (vs kr.5.77 loss in 1Q 2021)

Insufficient new directors

Zealand Pharma Announces CEO Changes

Full year 2021 earnings: Revenues in line with analyst expectations

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

First quarter 2021 earnings released: kr.5.78 loss per share (vs kr.4.98 loss in 1Q 2020)

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Full year 2020 earnings released: kr.22.07 loss per share (vs kr.16.91 loss in FY 2019)

Revenue misses expectations

New 90-day low: kr.192

New 90-day low: kr.202

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Third quarter 2020 earnings released: kr.5.76 loss per share

Revenue misses expectations

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

New 90-day low: kr.211

New 90-day high: kr.245

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

New 90-day low - kr.220

Rentabilidad de los accionistas